[1] Haring B, Kudlich T, Rauthe S, et al. Benzbromarone: a double-edged sword that cuts the liver? Eur J Gastroenterol & Hepatol, 2013, 25: 119-121.
[2] Chalasani N, Bonkovsky HL, Fontana R, et al; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology, 2015, 148: 1340-1352.
[3] Devarbhavi H, Raj S, Aradya VH, et al. Drug-induced liver injury associated with stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases. Hepatology, 2016, 63: 993-999.
[4] Charlton S, Le BH. Polypharmacy in palliative care: optimising medications is an ongoing challenge.Intern Med J, 2014,44: 619-620.
[5] Shibata S, Umemura T, Komatsu M, et al. Severe hepatotoxicity associated with asunaprevir and daclatasvir in chronic hepatitis C. Hepatology, 2016, 63: 2063-2064.
[6] Suga T, Sato K, Yamazaki Y, et al. Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World J Clin Cases, 2015,3: 1005-1010.
[7] Suzuki A, Yuen N A, Ilic K, et al. Corrigendum to “Comedications alter drug-induced liver injury reporting freq uency: Data mining in the WHO VigiBase TM”. Toxicol. Pharmacol, 2015,74: 481-490.
[8] Hayashi PH. Drug-induced liver injury network causality assessment: Criteria and Experience in the United States. Int J Mol Sci. 2016, 17. pii: E201. doi: 10.3390/ijms17020201.
[9] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014, 109: 950-966.
[10] Ghattaoraya GS, Dundar Y, González-Galarza FF, et al. A web resource for mining HLA associations with adverse drug reactions: HLA-ADR. Database (Oxford). 2016, pii: baw069. doi: 10.1093/database/baw069.
[11] Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. 2014, 509: 282-283.
[12] Powles T, Bracarda S, Chen M, et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer, 2015, 51: 1293-1302.
[13] Fujii Y, Uchida Y, Mochida S. Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. Hepatology, 2015, 61:400-401.
[14] Stanulovi V, Venegoni M, Edwards B. Intentional rechallenge: does the benefit outweigh the risk Drug Saf.,2013, 36: 155-161.
[15] Lucena MI, Kaplowitz N, Hallal H, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J hepatology, 2011, 55: 820-827.
[16] Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 2011, 89: 806-815.
[17] Jüngst C, Kim YJ, Lammert F. Severe drug-induced liver injury related to therapy with dimethyl fumarate. Hepatology, 2016, doi: 10.1002/hep.28652[Epub ahead of print].
[18] Takeda K, Oda M, Okada T, et al. Over-the-counter Drug Induced Autoimmune Hepatitis. Intern Med, 2016, 55: 1293-1297.
[19] Heidari R, Esmailie N, Azarpira N, et al. Effect of thiol-reducing agents and antioxidants on sulfasalazine-induced hepatic Injury in normotermic recirculating Isolated perfused rat liver.Toxicol Res, 2016, 32: 133-140.
[20] Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int., 2016, 36: 158-165.
[21] Silambarasan M, Tan JR, Karolina DS, et al. MicroRNAs in hyperglycemia induced endothelial cell dysfunction. Int J Mol Sci. 2016, 17. doi: 10.3390/ijms17040518.
[22] Win S, Than TA, Le BH, García-Ruiz C, et al. Sab (Sh3bp5) dependence of JNK mediated inhibition of mitochondrial respiration in palmitic acid induced hepatocyte lipotoxicity. J Hepatol, 2015, 62: 1367-1374.
[23] Win S, Than TA, Fernandez-Checa JC, et al. JNK interaction with Sab mediates ER stress induced inhibition of mitochondrial respiration and cell death. Cell Death Dis, 2014, 5:e989. doi: 10.1038.
[24] Spraggs CF, Xu CF, Hunt CM. Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. Pharmacogenomics, 2013, 14: 541-554.
[25] Andersson Y, Engebraaten O, Juell S, et al. Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. Br J Cancer. 2015, 113: 1548-1555.
[26] Chakraborty M, Fullerton AM, Semple K, et al. Drug-induced allergic hepatitis develops in mice when myeloid-derived suppressor cells are depleted prior to halothane treatment. Hepatology, 2015, 62: 546-557. |
